廣告
香港股市 已收市

  • 恒指

    19,608.30
    +54.69 (+0.28%)
     

  • 國指

    6,954.40
    +19.70 (+0.28%)
     

  • 上證綜指

    3,171.15
    +17.12 (+0.54%)
     

  • 道指

    40,003.59
    +134.19 (+0.34%)
     

  • 標普 500

    5,303.27
    +6.17 (+0.12%)
     

  • 納指

    16,685.97
    -12.33 (-0.07%)
     

  • Vix指數

    12.23
    +0.24 (+2.00%)
     

  • 富時100

    8,448.78
    +28.52 (+0.34%)
     

  • 紐約期油

    80.16
    +0.10 (+0.12%)
     

  • 金價

    2,443.60
    +26.20 (+1.08%)
     

  • 美元

    7.7986
    -0.0036 (-0.05%)
     

  • 人民幣

    0.9267
    +0.0014 (+0.15%)
     

  • 日圓

    0.0498
    -0.0001 (-0.10%)
     

  • 歐元

    8.4803
    -0.0018 (-0.02%)
     

  • Bitcoin

    66,921.16
    -326.89 (-0.49%)
     

  • CMC Crypto 200

    1,365.35
    +10.93 (+0.81%)
     

Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Equity Research
·2 分鐘文章

For the quarter ended March 2024, Insmed (INSM) reported revenue of $75.5 million, up 15.8% over the same period last year. EPS came in at -$1.06, compared to -$1.17 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $78.88 million, representing a surprise of -4.28%. The company delivered an EPS surprise of +13.11%, with the consensus EPS estimate being -$1.22.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

廣告

Here is how Insmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Japan: $14.89 million versus the two-analyst average estimate of $17.85 million.

  • Revenue- Europe and rest of world: $4.26 million compared to the $4.07 million average estimate based on two analysts.

  • Revenue- US: $56.35 million compared to the $55.61 million average estimate based on two analysts.

View all Key Company Metrics for Insmed here>>>

Shares of Insmed have returned -8.4% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insmed, Inc. (INSM) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research